Recensioni verificate Soddisfatta del servizio.
Personale disponibile e gentile. Lo consiglio a tutti ...
Cliente Sorgente Genetica
logomysorgente

02  4948  5291

  • Cos'è AURORA

    Aurora è il test di screening prenatale di ultima generazione 
    sicuro, affidabile,
    veloce e precoce

  • Sicuro

    Grazie a un semplice prelievo di sangue materno
    eviti il rischio di aborto di tecniche invasive come amniocentesi o villocentesi

  • Affidabile

    Oltre il 99,9% di affidabilità nel rilevare
    la trisomia 21, responsabile
    della Sindrome di Down

  • Precoce e veloce

    icona svegliaIndividuare precocemente la presenza di anomalie cromosomiche è fondamentale:
    puoi effettuare Aurora dalla 10ª settimana

    icona documentoIl test è veloce: risultati in 7-10 giorni lavorativi con la percentuale di test da ripetere più bassa del mercato: 0,1%

  • La serenità della mamma
    in 3 semplici passi

    icotelefona

    Prenota il test

    icoesami

    Fai un prelievo di sangue

    icoginecologo

    Leggi i risultati

  • Test diagnosi prenatale non invasivo
  • 151126 banner Aurora mobile 01
  • 151126 banner Aurora mobile 02
  • 151126 banner Aurora mobile 03
  • slide mobile03
cover cartoon
cover venturetti

Ultime notizie dal mondo della genetica


BRCA genes double the risk of prostate cancer

Men positive for BRCA gene variants are twice as likely to get prostate cancer. This was revealed by a study by the Institute of Cancer Research, London. The researchers examined the DNA of nearly 1,400 volunteers, of which 902 were carriers of the variants. BRCA2 gene abnormalities are associated with a higher risk of breast and ovarian cancer. Port women of the variant have between 50% and 85% suffering from breast cancer by age 70. However, this study focuses on the consequences of the gene in men, much less taken into consideration. Not always the normal tests for prostate cancer are enough: several studies prove it.

The analysis of PSA antigen alone, specifically linked to this pathology, is not applicable to the general population. On the other hand, the tests in question showed that BRCA2 carriers were more prone to severe cancers. The researchers then decided to investigate the issue.

The study includes genetic data of 902 carriers and 497 non-BRCA2 carriers. The researchers analyzed how many of the analyzed subjects were affected or would suffer from prostate cancer. About 40% of the non-gene carriers suffered from clinically relevant diseases, compared to 77% in the other group. Furthermore, the latter were twice as likely to develop cancer.

Source: telegraph.co.uk

Link social

Link social